AKT1 and cancer: Previous studies have shown that CXCR2 can be activated by CXCL5 or other ligands to stimulate cancer progression through the activation of downstream pathways, such as JAK/STAT3, JNK, PI3K/AKT and ERK1/2 pathway [13, 14].